51
|
Abstract
Subcutaneous mycoses include a heterogeneous group of fungal infections that develop at the site of transcutaneous trauma. Infection slowly evolves as the etiologic agent survives and adapts to the adverse host tissue environment. Diagnosis rests on clinical presentation, histopathology, and culture of the etiologic agents. This article considers sporotrichosis, chromoblastomycosis, and mycetoma.
Collapse
|
52
|
Bonifaz A, Peniche A, Mercadillo P, Saúl A. Successful treatment of AIDS-related disseminated cutaneous sporotrichosis with itraconazole. AIDS Patient Care STDS 2001; 15:603-6. [PMID: 11788073 DOI: 10.1089/108729101753354581] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Sporotrichosis is a chronic granulomatous mycosis caused by a dimorphic fungus, Sporothrix schenckii. The most common manifestations of infection are lymphocutaneous and fixed-cutaneous types. In the case of immunosuppressed patients, and particularly in patients with acquired immune deficiency syndrome (AIDS), it occurs as disseminated cutaneous disease. This is a report of a 28-year-old male patient who presented with disseminated cutaneous and hematogenous sporotrichosis involving multiple ulcerative, nodular lesions in various body areas. Treatment consisted of 300 mg/d of itraconazole, which resulted in clinical and mycological cure.
Collapse
Affiliation(s)
- A Bonifaz
- Dermatology Service and Mycology Department, Hospital General de México OD, Mexico City, Mexico.
| | | | | | | |
Collapse
|
53
|
Kauffman CA, Hedderwick SA. Treatment of systemic fungal infections in older patients: achieving optimal outcomes. Drugs Aging 2001; 18:313-23. [PMID: 11392440 DOI: 10.2165/00002512-200118050-00002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Systemic fungal infections are an increasing problem in older adults. For several of the endemic mycoses, this increase is the result of increased travel and leisure activities in areas endemic for these fungi. Immunosuppressive agents, care in an intensive care unit, and invasive devices all contribute to infection with opportunistic fungi. Treatment of systemic fungal infections is usually with an azole or amphotericin B. The preferred regimen depends on the specific fungal infection, the site and the severity of the infection, the state of immunosuppression of the patient and the possible toxicities of each drug for a specific patient. In older adults, drug-drug interactions between the azoles and drugs commonly prescribed for older persons may lead to serious toxicity, and absorption of itraconazole can be problematic. Amphotericin B is associated with significant nephrotoxicity, especially in older adults with pre-existing renal disease, and infusion-related adverse effects. Newer lipid formulations of amphotericin B can obviate some of these toxicities, but their role in the treatment of systemic fungal infections in older adults has not yet been clarified.
Collapse
Affiliation(s)
- C A Kauffman
- Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, University of Michigan Medical School, 48105, USA.
| | | |
Collapse
|
54
|
Gordhan A, Ramdial PK, Morar N, Moodley SD, Aboobaker J. Disseminated cutaneous sporotrichosis: a marker of osteoarticular sporotrichosis masquerading as gout. Int J Dermatol 2001; 40:717-9. [PMID: 11737440 DOI: 10.1046/j.1365-4362.2001.01300.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A Gordhan
- Departments of Dermatology and Anatomical Pathology, Nelson R Mandela School of Medicine, University of Natal, Durban, South Africa
| | | | | | | | | |
Collapse
|
55
|
Sykes JE, Torres SM, Armstrong PJ, Lindeman CJ. Itraconazole for treatment of sporotrichosis in a dog residing on a Christmas tree farm. J Am Vet Med Assoc 2001; 218:1440-3, 1421. [PMID: 11345307 DOI: 10.2460/javma.2001.218.1440] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Sporotrichosis was diagnosed in a 2-year-old male Golden Retriever that was allowed to roam free on the owner's Christmas tree farm in Minnesota. Clinical signs had been evident for 1 month and included swelling of the claw bed of the third digit on the left forelimb and a fluctuant nodular lesion in the area of the left carpus. Few organisms were seen in affected tissues, and diagnosis was confirmed on the basis of results of fungal culture. The condition responded to treatment with itraconazole. Previous reports of sporotrichosis in dogs have described lesions that were distributed predominantly on the head, ears, and trunk. A history of exposure to environments that favor survival of the organism may be an important consideration when evaluating animals suspected to have sporotrichosis. To the authors' knowledge, use of itraconazole to treat a dog with sporotrichosis has not been reported previously.
Collapse
Affiliation(s)
- J E Sykes
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA
| | | | | | | |
Collapse
|
56
|
Abstract
The incidence of fungal infections is increasing at an alarming rate, presenting an enormous challenge to healthcare professionals. This increase is directly related to the growing population of immunocompromised individuals, resulting from changes in medical practice such as the use of intensive chemotherapy and immunosuppressive drugs. HIV and other diseases which cause immunosuppression have also contributed to this problem. Superficial and subcutaneous fungal infections affect the skin, keratinous tissues and mucous membranes. Included in this class are some of the most frequently occurring skin diseases, affecting millions of people worldwide. Although rarely life threatening, they can have debilitating effects on a person's quality of life and may in some circumstances spread to other individuals or become invasive. Most superficial and subcutaneous fungal infections are easily diagnosed and readily amenable to treatment. Systemic fungal infections may be caused by either an opportunistic organism that infects an at-risk host, or may be associated with a more invasive organism that is endemic to a specific geographical area. Systemic infections can be life threatening and are associated with high morbidity and mortality. Because diagnosis is difficult and the causative agent is often confirmed only at autopsy, the exact incidence of systemic infections is difficult to determine. The most frequently encountered pathogens are Candida albicans and Aspergillus spp. but other fungi such as non-albicans Candida spp. are increasingly important.
Collapse
Affiliation(s)
- G Garber
- Infectious Diseases Division, Ottawa Hospital, Ontario, Canada.
| |
Collapse
|
57
|
Pelzer K, Tietz HJ, Sterry W, Haas N. Isolation of both Sporothrix schenckii and Nocardia asteroides from a mycetoma of the forefoot. Br J Dermatol 2000; 143:1311-5. [PMID: 11122041 DOI: 10.1046/j.1365-2133.2000.03908.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Mycetoma is a localized primary subcutaneous infection due to fungi (eumycetoma) or aerobic actinomycetes (actinomycetoma). We report a patient who acquired an implantation infection on the forefoot following a motorcycle accident in Crete. Both Sporothrix schenckii and Nocardia asteroides were isolated simultaneously from the lesion. Under combined therapy with itraconazole and trimethoprim-sulphamethoxazole for 7 months the lesion healed completely. A combination of causative organisms in mycetomas is rare, and the combination of S. schenckii and N. asteroides together has not been reported from one lesion.
Collapse
Affiliation(s)
- K Pelzer
- Department of Dermatology, Medical Faculty (Charité), Humboldt-University Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany
| | | | | | | |
Collapse
|
58
|
Wang JP, Granlund KF, Bozzette SA, Botte MJ, Fierer J. Bursal sporotrichosis: case report and review. Clin Infect Dis 2000; 31:615-6. [PMID: 10987734 DOI: 10.1086/313983] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
We describe a patient whose prepatellar bursa was infected with Sporothrix schenckii. The infection persisted despite itraconazole therapy and cure was achieved only after surgical excision of the bursa. A review of treatments for bursal sporotrichosis is presented.
Collapse
Affiliation(s)
- J P Wang
- Divisions of Infectious Diseases and Orthopedic Surgery, University of California, San Diego, CA, 92161, USA
| | | | | | | | | |
Collapse
|
59
|
Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:684-7. [PMID: 10770730 DOI: 10.1086/313751] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/1999] [Revised: 06/14/1999] [Indexed: 11/03/2022] Open
Abstract
UNLABELLED The recommendations for the treatment of sporotrichosis were derived primarily from multicenter, nonrandomized treatment trials, small retrospective series, and case reports; no randomized, comparative treatment trials have been reported. Most cases of sporotrichosis are non life-threatening localized infections of the skin and subcutaneous tissues that can be treated with oral antifungal agents. The treatment of choice for fixed cutaneous or lymphocutaneous sporotrichosis is itraconazole for 36 months. The preferred treatment for osteoarticular sporotrichosis also is itraconazole, but therapy must be continued for at least 12 months. Pulmonary sporotrichosis responds poorly to treatment. Severe infection requires treatment with amphotericin B; mild to moderate infection can be treated with itraconazole. Meningeal and disseminated forms of sporotrichosis are rare and usually require treatment with amphotericin B. AIDS patients most often have disseminated infection and require life-long suppressive therapy with itraconazole after initial use of amphotericin B. OVERVIEW Sporotrichosis is caused by the dimorphic fungus Sporothrix schenckii, which is found throughout the world in decaying vegetation, sphagnum moss, and soil. The usual mode of infection is by cutaneous inoculation of the organism. Pulmonary and disseminated forms of infection, although uncommon, can occur when S. schenckii conidia are inhaled. Infections are most often sporadic and usually associated with trauma during the course of outdoor work. Infection can also be related to zoonotic spread from infected cats or scratches from digging animals, such as armadillos. Outbreaks have been well-described and often are traced back to activities that involved contaminated sphagnum moss, hay, or wood. Most cases of sporotrichosis are localized to the skin and subcutaneous tissues. Dissemination to osteoarticular structures and viscera is uncommon and appears to occur more often in patients who have a history of alcohol abuse or immunosuppression, especially AIDS. Spontaneous resolution of sporotrichosis is rare, and treatment is required for most patients. Although sporotrichosis localized to skin and subcutaneous tissues is readily treated, management of osteoarticular, other localized visceral, and disseminated forms of sporotrichosis is difficult. OBJECTIVE The objective of these guidelines is to provide recommendations for the treatment of various forms of sporotrichosis. OUTCOMES The desired outcomes of treatment include eradication of S. schenckii from tissues, resolution of symptoms and signs of active infection, and return of function of involved organs. In persons with AIDS, eradication of the organism may not be possible, but clinical resolution should be attained and subsequently maintained with suppressive antifungal therapy. EVIDENCE The English-language literature on the treatment of sporotrichosis was reviewed. Although randomized, blinded, controlled treatment trials were sought, none were found to have been performed for the treatment of sporotrichosis. Therefore, most weight was placed on those reports that were derived from multicenter trials of specific treatment modalities for sporotrichosis. Small series from a single institution and individual case reports were accorded less importance. VALUES The highest value was placed on clinical efficacy and the ability of the antifungal regimen to eradicate the organism, but safety, tolerability, and cost of therapy were also valued. BENEFITS AND COSTS: The benefits of successfully treating sporotrichosis accrue primarily for the patient. Because this infection is not spread from person-to-person, public health aspects of treatment are of minor importance. Most forms of sporotrichosis are not life-threatening; thus, therapy is aimed at decreasing morbidity, improving quality of life, and allowing the patient to return to occupational and familial pursuits. (ABSTRACT TRUNCATED)
Collapse
Affiliation(s)
- C A Kauffman
- Division of Infectious Diseases, University of Michigan Medical School and Veterans Affairs Medical Center, Ann Arbor 48105, USA.
| | | | | |
Collapse
|
60
|
Abstract
Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial fungal infections including difficult-to-treat dermatophytoses and onychomycoses. Furthermore, shortened treatment regimens have proven to be effective, ranging from 1-day treatment for vaginal candidosis to 1-week pulse therapy per month, for 2-4 months, in onychomycosis and follicular dermatophytosis. Clinical experience with itraconazole in the treatment of deep mycoses is less comprehensive. However, results in systemic candidosis, sporotrichosis, blastomycosis, paracoccidioiodomycosis, certain types of histoplasmosis and aspergillosis are extremely encouraging. Itraconazole is less effective in the treatment of chromomycosis and coccidioidomycosis. Nevertheless, considering the refractory nature of these diseases, itraconazole has proven to be a valuable addition to the antifungal drugs currently available for treatment. Itraconazole has been well-tolerated with doses of up to 400 mg/day being generally free of serious adverse effects. However, a potential for drug interactions exists, mediated through the cytochrome P450 enzyme 3A4 system, which should be considered when itraconazole is used as part of a multi-drug regimen.
Collapse
Affiliation(s)
- G E Piérard
- Department of Dermatopathology, Institute of Pathology, University Medical Center of Liège, Belgium.
| | | | | |
Collapse
|
61
|
Pappas PG, Tellez I, Deep AE, Nolasco D, Holgado W, Bustamante B. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis 2000; 30:65-70. [PMID: 10619735 DOI: 10.1086/313607] [Citation(s) in RCA: 120] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Sporotrichosis is a sporadic and rare mycotic infection in most of the developed world. In many parts of the developing world, sporotrichosis is much more commonly recognized, but epidemiological data are generally lacking from these regions. We report epidemiological, clinical, and treatment data from 238 cases of culture-proven sporotrichosis occurring in a relatively remote area of the south central highlands of Peru that were retrospectively collected during 1995-1997. Most cases (60%) occurred in children aged </=14 years, and the most commonly affected anatomic site was the face. Disease was clinically confined to the skin and subcutaneous tissue in all patients. The incidence of sporotrichosis in this region ranged from 48 to 60 cases per 100,000 persons and was highest among children aged 7-14 years, approaching 1 case per 1000 persons. Sporotrichosis is a significant mycosis in the rural highlands of Peru, with an incidence exceeding those of other invasive mycoses in individuals without human immunodeficiency virus infection.
Collapse
Affiliation(s)
- P G Pappas
- Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA. ppappas@uabid. dom.uab.edu
| | | | | | | | | | | |
Collapse
|
62
|
Bonifaz A, Saúl A, Montes-de-Oca G, Mercadillo P. Superficial cutaneous sporotrichosis in specific anergic patient. Int J Dermatol 1999; 38:700-3. [PMID: 10517689 DOI: 10.1046/j.1365-4362.1999.00742.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A Bonifaz
- Department of Mycology, General Hospital of Mexico, Mexico DF
| | | | | | | |
Collapse
|
63
|
Abstract
A woman presented with a swollen red leg of 2 weeks' duration. Culture of the skin biopsy specimen confirmed this to be an infection caused by Sporothrix schenckii. Systemic evaluation led to the diagnosis of Cushing's disease and explained the unusual morphology. Treatment-related complications are also discussed.
Collapse
Affiliation(s)
- S Kim
- Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, USA
| | | | | |
Collapse
|
64
|
Ware AJ, Cockerell CJ, Skiest DJ, Kussman HM. Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS. J Am Acad Dermatol 1999; 40:350-5. [PMID: 10025867 DOI: 10.1016/s0190-9622(99)70484-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Sporotrichosis most commonly presents as a localized, lymphocutaneous infection that follows trauma, such as an injury from a rose thorn. In patients infected with HIV, it may be widespread and disseminated. We describe a patient with AIDS who developed disseminated sporotrichosis, a rare opportunistic fungal infection that may affect these patients. The condition remained undiagnosed because of failure to recognize characteristic histopathologic findings and failure of clinicians to interface closely with the microbiology laboratory. The condition was difficult to treat, requiring systemic administration of amphotericin. While localized sporotrichosis is an innocuous disorder that responds well to therapy, in immunocompromised hosts, it is potentially life-threatening and may require prolonged therapy with potentially toxic medications such as amphotericin B. It is important that clinicians be aware of the presentation of this unusual opportunistic infection and that they maintain close communication with pathology and clinical microbiology laboratories to ensure that proper stains and cultures are performed to avoid potential misdiagnosis.
Collapse
Affiliation(s)
- A J Ware
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA
| | | | | | | |
Collapse
|
65
|
P. Neto RDJ, Machado AA, Castro GD, Quaglio ASDS, Martinez R. Esporotricose cutânea disseminada como manifestação inicial da síndrome da imunodeficiência adquirida - relato de caso. Rev Soc Bras Med Trop 1999. [DOI: 10.1590/s0037-86821999000100011] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Os autores relatam caso de infecção cutânea disseminada pelo Sporothrix schenckii em paciente de 30 anos, previamente assintomático e portador de infecção pelo HIV. Observou-se comprometimento cutâneo extenso com coleções supurativas e ulcerações. O agente foi isolado em cultura de abscesso. O tratamento com anfotericina B forma lipossomal mostrou-se eficaz.
Collapse
|
66
|
Abstract
Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
Collapse
Affiliation(s)
- D J Sheehan
- Pfizer Pharmaceuticals Group, Pfizer Inc., New York, New York 10017-5755, USA.
| | | | | |
Collapse
|
67
|
Abstract
Before 1978, amphotericin B and flucytosine were the only drugs available for the treatment of systemic fungal infections. The imidazoles, miconazole and ketoconazole, were introduced during the next 3 years. Intravenously administered miconazole served a limited therapeutic role and is no longer available. Orally administered ketoconazole, an inexpensive, effective, and convenient option for treating mucosal candidiasis, was widely used for a decade because it was the only available oral therapy for systemic fungal infections. During the 1990s, use of ketoconazole diminished because of the release of the triazoles--fluconazole and itraconazole. Fluconazole is less toxic and has several pharmacologic advantages over ketoconazole, including penetration into the cerebrospinal fluid. In addition, it has superior efficacy against systemic candidiasis, cryptococcosis, and coccidioidomycosis. Despite a myriad of drug interactions and less favorable pharmacologic and toxicity profiles in comparison with fluconazole, itraconazole has become a valuable addition to the antifungal armamentarium. It has excellent activity against sporotrichosis and seems promising in the treatment of aspergillosis. Itraconazole has replaced ketoconazole as the therapy of choice for nonmeningeal, non-life-threatening cases of histoplasmosis, blastomycosis, and paracoccidioidomycosis and is effective in patients with cryptococcosis and coccidioidomycosis, including those with meningitis. Further investigation into the development of new antifungal agents is ongoing.
Collapse
Affiliation(s)
- C L Terrell
- Division of Allergy and Outpatient Infectious Disease and Internal Medicine, Mayo Clinic Rochester, Minnesota 55905, USA
| |
Collapse
|
68
|
Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1998; 44:343-500. [PMID: 9547888 DOI: 10.1016/s1054-3589(08)60129-5] [Citation(s) in RCA: 288] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- A H Groll
- Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
69
|
Polak A. Antifungal therapy, an everlasting battle. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1997; 49:219-318. [PMID: 9388389 DOI: 10.1007/978-3-0348-8863-9_7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
70
|
Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1997; 39:143-89. [PMID: 9160115 DOI: 10.1016/s1054-3589(08)60071-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- C A Kauffman
- Department of Internal Medicine, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
| | | |
Collapse
|
71
|
Abstract
With AIDS has come a new level of T-cell immunosuppression, beyond that previously seen. The impact of the HIV pandemic on the field of fungal infections includes a major increase in the number of serious fungal infections, an increase in the severity of those infections, and even some entirely new manifestations of fungal illness. In this article fungal pulmonary complications of AIDS are discussed. T-cell opportunists including Cryptococcus neoformans and the endemic mycoses are the most important pathogens. Phagocyte opportunists, including Aspergillus species and agents of mucormycosis, are less important.
Collapse
Affiliation(s)
- S F Davies
- Department of Medicine, Hennepin County Medical Center, USA
| | | |
Collapse
|
72
|
|
73
|
Affiliation(s)
- A Espinel-Ingroff
- Medical Mycology Research Laboratory, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA
| |
Collapse
|
74
|
Abstract
A 36 year old Samoan male who developed cutaneous sporotrichosis as a result of traditional body tattooing is reported. It is considered that the tattooing procedure was responsible for introducing the infection. He was treated with itraconazole, which produced resolution of the lesions.
Collapse
Affiliation(s)
- K Y Choong
- Dermatology Outpatient Department, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
| | | |
Collapse
|
75
|
Affiliation(s)
- B M Clay
- Department of Surgery, University of Mississippi Medical Center, Jackson 39216-4505, USA
| | | |
Collapse
|
76
|
|
77
|
Graybill JR. Antifungal drugs and resistance. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1995; 390:217-34. [PMID: 8718616 DOI: 10.1007/978-1-4757-9203-4_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- J R Graybill
- Department of Medicine, Audie Murphy V.A. Hospital, San Antonio, TX, USA
| |
Collapse
|
78
|
Hoeprich PD. Antifungal chemotherapy. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1995; 44:87-127. [PMID: 7644668 DOI: 10.1007/978-3-0348-7161-7_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
79
|
MATSUURA KYOKO. Two cases of the lymph duct type sporotrichosis in which itraconazole internal use was effective. ACTA ACUST UNITED AC 1995. [DOI: 10.2336/nishinihonhifu.57.379] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
80
|
|
81
|
Coskey RJ. Dermatologic therapy: 1993. J Am Acad Dermatol 1994; 31:764-74. [PMID: 7929923 DOI: 10.1016/s0190-9622(94)70239-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
This article reviews some therapeutic results reported in the English-language literature during 1993. Readers should review the original article in full before attempting any experimental or controversial therapy.
Collapse
Affiliation(s)
- R J Coskey
- Dermatology Department, Wayne State University School of Medicine, Detroit, Michigan
| |
Collapse
|
82
|
Abstract
In the past, few pharmacologic agents were available for management of fungal disease. After the early introduction of amphotericin B and miconazole, the more recent advent of several new antifungal agents, including ketoconazole, fluconazole, and itraconazole has expanded the options for treatment of fungal infections. The dramatic increase in number of immunocompromised patients--both those with acquired immunodeficiency syndrome (AIDS) and those with immunosuppression for other reasons, such as organ transplantation--emphasizes the importance of therapeutic strategies for combating systemic mycoses. In this article, we review our personal recommendations for treating histoplasmosis, blastomycosis, coccidioidomycosis, and cryptococcosis, along with other less common fungal infections, and discuss the efficacy and toxic effects of the various antifungal drugs.
Collapse
Affiliation(s)
- G A Sarosi
- Department of Medicine, Santa Clara Valley Medical Center, San Jose, California
| | | |
Collapse
|
83
|
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. CASE 28-1994. A 51-year-old man with a nonhealing finger wound and regional lymphadenopathy. N Engl J Med 1994; 331:181-7. [PMID: 7999146 DOI: 10.1056/nejm199407213310308] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
84
|
Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur J Clin Microbiol Infect Dis 1994; 13:609-12. [PMID: 7805693 DOI: 10.1007/bf01971316] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
An AIDS patient with sporotrichosis who improved with itraconazole therapy after consecutive failure of ketoconazole, saturated solution of potassium iodide, fluconazole and amphotericin B is presented. In addition, long-term therapy with high doses of itraconazole was well tolerated and effective in avoiding relapse. Itraconazole may be suitable for use in HIV-infected patients with sporotrichosis, who probably require chronic suppressive therapy to prevent relapse of symptomatic disease.
Collapse
Affiliation(s)
- F Bolao
- Infectious Disease Service, Ciutat Sanitaria de Bellvitge, University of Barcelona, Spain
| | | | | | | |
Collapse
|
85
|
Zuckerman JM, Tunkel AR. Itraconazole: A New Triazole Antifungal Agent. Infect Control Hosp Epidemiol 1994. [DOI: 10.2307/30145593] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
86
|
Abstract
The oral azole drugs--ketoconazole, fluconazole, and itraconazole--represent a major advance in systemic antifungal therapy. Among the three, fluconazole has the most attractive pharmacologic profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine. Ketoconazole, the first oral azole to be introduced, is less well tolerated than either fluconazole or itraconazole and is associated with more clinically important toxic effects, including hepatitis and inhibition of steroid hormone synthesis. However, ketoconazole is less expensive than fluconazole and itraconazole--an especially important consideration for patients receiving long-term therapy. All three drugs are effective alternatives to amphotericin B and flucytosine as therapy for selected systemic mycoses. Ketoconazole and itraconazole are effective in patients with the chronic, indolent forms of the endemic mycoses, including blastomycosis, coccidioidomycosis, and histoplasmosis; itraconazole is also effective in patients with sporotrichosis. Fluconazole is useful in the common forms of fungal meningitis--namely, coccidioidal and cryptococcal meningitis. In addition, fluconazole is effective for selected patients with serious candida syndromes such as candidemia, and itraconazole is the most effective of the azoles for the treatment of aspergillosis.
Collapse
Affiliation(s)
- J A Como
- Department of Medicine, University of Alabama, Birmingham School of Medicine
| | | |
Collapse
|